Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 25;26(23):7141.
doi: 10.3390/molecules26237141.

Treatment of Benign Prostatic Hyperplasia by Natural Drugs

Affiliations
Review

Treatment of Benign Prostatic Hyperplasia by Natural Drugs

Eszter Csikós et al. Molecules. .

Abstract

Benign prostatic hyperplasia (BPH) is one of the most common urinary diseases affecting men, generally after the age of 50. The prevalence of this multifactorial disease increases with age. With aging, the plasma level of testosterone decreases, as well as the testosterone/estrogen ratio, resulting in increased estrogen activity, which may facilitate the hyperplasia of the prostate cells. Another theory focuses on dihydrotestosterone (DHT) and the activity of the enzyme 5α-reductase, which converts testosterone to DHT. In older men, the activity of this enzyme increases, leading to a decreased testosterone/DHT ratio. DHT may promote prostate cell growth, resulting in hyperplasia. Some medicinal plants and their compounds act by modulating this enzyme, and have the above-mentioned targets. This review focuses on herbal drugs that are most widely used in the treatment of BPH, including pumpkin seed, willow herb, tomato, maritime pine bark, Pygeum africanum bark, rye pollen, saw palmetto fruit, and nettle root, highlighting the latest results of preclinical and clinical studies, as well as safety issues. In addition, the pharmaceutical care and other therapeutic options of BPH, including pharmacotherapy and surgical options, are discussed, summarizing and comparing the advantages and disadvantages of each therapy.

Keywords: benign prostatic hyperplasia; clinical efficacy; medicinal plants; phytotherapy; preclinical studies; safety issues; saw palmetto.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Madersbachera S., Alivizatosb G., Nordling J., Nordling J., Sanz C.R., Emberton M., Rosette J. EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines) Eur. Urol. 2004;46:547–554. doi: 10.1016/j.eururo.2004.07.016. - DOI - PubMed
    1. De la Rosettea J.J.M.C.H., Alivizatosb G., Madersbacher S. EAU Guidelines on Benign Prostatic Hyperplasia (BPH) Eur. Urol. 2001;40:256–263. doi: 10.1159/000049784. - DOI - PubMed
    1. Yanoshak S., Roehrborn C., Girman C., Jaffe J.S., Ginsberg P.C., Harkaway R.C. Use of a prostate model to assist in training for digital rectal examination. Urology. 2000;55:690–693. doi: 10.1016/S0090-4295(99)00606-8. - DOI - PubMed
    1. Allkanjari O., Vitalone A. What do we know about phytotherapy of benign prostatic hyperplasia? Life Sci. 2015;126:42–56. doi: 10.1016/j.lfs.2015.01.023. - DOI - PubMed
    1. Jonler M., Riehmann M., Brinkmann R., Bruskewitz R.C. Benign prostatic hyperplasia. Endocrinol. Metab. Clin. N. Am. 1994;4:795–807. doi: 10.1016/S0889-8529(18)30068-9. - DOI - PubMed

MeSH terms

LinkOut - more resources